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Abstract Detection of molecular markers for colorectal
neoplasia in feces has the potential to improve performance
of simple noninvasive screening tests for colorectal cancer.
Most research has explored the value of DNA-based, RNA-
based, and protein-based markers. In all cases there has
been a trend to move from a single marker to a panel of
markers to improve sensitivity. Unfortunately, no type of
molecular marker has proved specific for neoplasia. DNA
tests have been improved by combining mutation detection
with assessment of DNA integrity plus epigenetic markers
of neoplasia. RNA-based approaches are just beginning to
explore the full power of transcriptomics. So far, no
protein-based fecal test has proved better than fecal
immunochemical tests for hemoglobin. Finally, no marker
or panel of markers has yet been developed to the point
where it has been evaluated in large unbiased population
studies to assess performance across all stages of neoplasia
and in all practical environments.
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Introduction
Progressive genomic instability in the colorectum gives rise
to colorectal cancer (CRC) due to the accumulation of
genetic alterations (gene mutations, gene amplification,
etc.) and epigenetic alterations (aberrant DNA methylation,
chromatin modifications, etc.) that transform epithelial cells
into carcinoma cells. Altered function of proto-oncogenes
and tumor suppressor genes results in disturbances of
biological processes such as DNA repair, proliferation,
and apoptosis. Several different molecular pathways of
oncogenesis have been defined [1￿, 2]. Our understanding
of the underlying and associated molecular changes is
increasing; specific changes at the DNA, RNA, and protein
levels are being discovered as well as metabolic and other
changes. These “molecular” changes have the potential to
serve as biomarkers for neoplasia and may be useful for
screening, diagnosis, prognostication, predicting responses
to therapy, and detecting recurrence provided that they can
be measured in biological materials such as blood or feces.
This review aims to provide an update on the concepts
underlyingtheuseofmolecularbiomarkersforscreening,how
new biomarkers can be evaluated, and which show promise
for use in screening. We will not consider tests for fecal blood
in this review, even though some specifically target the
hemoglobin molecule (ie, fecal immunochemical tests, FIT
[3￿]) nor will we consider blood-based molecular tests which
are fast becoming an increasingly active area of research.
Proven Simple Screening Tests
Multiple population-based randomized trials have proved
that guaiac-based fecal occult blood tests (GFOBT) detect
early-stage disease and result in a reduced mortality from
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of lesions with a “bleeding phenotype” is beneficial in that
one can be confident that treatment (surgery, polypectomy,
etc.) will result in worthwhile gains.
A single targeted population-based randomized trial has
provedthatflexiblesigmoidoscopydetectsearly-stagedisease
and results in a reduced mortality from and incidence of CRC
[6￿￿]. Detection by endoscopic methods requires only that a
lesion be visualizable and since such is independent of the
bleeding phenotype, this trial indicates that treatment benefit
for early neoplastic lesions is probably independent of tumor
phenotype or genotype. This is a crucial point because
expression of a molecular biomarker by a tumor might
reflect a certain biological behavior that reflects natural
history or is related to or determines response to therapy. For
example, a lesion might grow so slowly as to not even need
treatment within a lifetime or, conversely, it might be so
aggressive as to render curative treatment pointless.
Evaluating New Screening Biomarkers
There are relatively few practical guidelines on how best to
compare “new” with proven screening tests and it is not the
purpose of this review to critique these strategies but it is
clear that new tests cannot be initially subject to random-
ized controlled trials (RCTs) with mortality or incidence as
the end point. Strategically, it is expedient to evaluate a
biomarker’s diagnostic performance relative to a proven
comparator screening test in highly selected cases with
cancer [7]. But evaluation of test accuracy must be backed
up by programmatic evaluation in the screening context
where prevalence is low and non-neoplastic lesions are
present [8] such that we know how the test performs across
the spectrum of prevalent neoplastic lesions. Such is
essential for a new test to be adopted for widespread use.
A phased evaluation of a new biomarker is recommended
[8]. Initial evaluation of biomarkers will usually be under-
taken in small numbers of highly selected cases, often
retrospective (such as those with symptomatic cancer versus
normal controls) and using colonoscopy as the reference
standard [9]. If promising, evaluation should proceed to
comparison with a proven screening test such as an FOBT
(ideally a FIT [3￿]) but such need not include cancer-specific
mortality as an end point provided that the comparator test’s
effect on population mortality has been proven by a
population randomized controlled trial [7]. Guaiac-FOBT
effectiveness represents the minimum standard to be
achieved by a new test since GFOBT are effective (albeit
limited) and inexpensive. Finally, a prospective evaluation of
performance across the continuum of neoplastic lesions from
adenoma to cancer should be undertaken in large unselected
typical screening populations.
Such comparative studies focus initially on relative
detection, but screening is about more than detection; it is
about success when applied to many healthy people where
disease prevalence is low and acceptability of the test is
crucial. Demonstration of adequate accuracy in prescreen-
ing phases justifies progression to mass-population studies
that address programmatic outcomes on an intention-to-
screen basis followed by evaluation of cost-effectiveness in
ongoing screening.
It will be apparent from the following discussions that
fecal molecular tests have not yet progressed to evaluation
by randomized fashion in large unselected populations.
How Might Molecular Markers Improve Screening
Outcomes?
Screening by existing proven methods has disadvantages
one way or another. Endoscopic methods are invasive and
inconvenient and when used as the primary screening tool
are used on many people who will prove to have no
neoplastic lesions in the colon. FOBT methods, while
simple and increasing the likelihood of neoplasia being
present when positive, are not specific for neoplasia, and
have somewhat limited sensitivity for cancer and especially
adenomas [9, 10], although FIT are a major improvement
over GFOBT [3￿].
It would be useful to have simple and acceptable
noninvasive screening tests that are more specific for
neoplasia, ie, have a lower false-positive rate. If so, this
will reduce costs of diagnostic follow-up, workloads, and
overall program cost.
It would also be valuable if simple and acceptable
noninvasive screening tests were more sensitive for curable
cancer and more advanced adenomas, ie, return a higher
true-positive rate. This would improve impact on mortality
and incidence.
While it is known that limitations of existing simple
tests, namely FOBT, include lack of specificity for
neoplasia and variation between tumors as to whether they
bleed or not [11], it needs to be shown, if simple molecular
tests are to replace FOBT, that they do indeed point to
molecular phenomena that are either more predictable than
bleeding and/or more characteristic of neoplasia.
Finally, sensitivity and specificity are both important and
improving one at the expense of the other does not
necessarily provide an advantage.
Detection of Neoplasia Using Biomarkers
Colorectal oncogenesis follows several genetic pathways
[1￿, 2]. The process is protracted and takes years, perhaps
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until sufficient molecular events accumulate to change cell
behavior and result in the invasive phenotype (ie, cancer)
[1￿, 12]. This sequence underlies the phenotypic progres-
sion known as the adenoma-carcinoma sequence. The stage
of neoplasia at which a biomarker becomes expressed and
detectable (ie, “positive”) is crucial to what we hope
molecular biomarkers will detect in the screening context.
A positive biomarker initiates diagnostic confirmation by
colonoscopy.
Figure 1 provides a conceptual presentation of the most
advanced stage of colorectal neoplasia reached by the time
of death (“life-time state”) for a typical Western population
[11￿￿]. Curable neoplastic lesions are the obvious target.
Curable cancer (point C in the process in Fig. 1) is a key
target, as the GFOBT RCTs showed that detection of
curable cancer (ie, downstaging of cancer) leads to
reduction in mortality [4]. Detection and removal of
adenomas (particularly advanced adenomas, point B in
Fig. 1) is also a worthwhile target as the flexible
sigmoidoscopy RCT showed a reduction in incidence as
did one GFOBT RCT [5, 6￿￿]. These studies support the
recent US multi-society guidelines that recommended that
screening target not just early-stage cancer but also
“advanced” adenomas [13￿￿]. Advanced adenomas are
defined as those of >9 mm, those with villous change, or
those showing high-grade dysplasia [14].
It can be seen that different biomarkers might characterize
differentstagesofoncogenesis andsovaryintheir usefulness.
Small, tubular, low-grade adenomas (point A in Fig. 1)
are more common than large, high-grade, or villous lesions.
Detection of early, small adenomas might not be useful in
that they pose little risk for CRC [15]—detection of
inconsequential neoplastic lesions is referred to as over-
diagnosis and is a major issue for prostate cancer screening
[16]. Detection of incurable neoplasia (biomarker point D
in Fig. 1), likewise, would not lead to benefit.
In other words, there is a gradation of probability of
progression from adenoma to cancer, with the more
advanced lesions more likely to progress to cancer;
biomarkers for adenomas will vary in their capacity to
predict likelihood of progression to cancer according to the
stage detected, as not all small adenomas progress to
advanced adenomas [14, 17, 18], and test sensitivity.
It also needs to be noted that with the different molecular
pathways of oncogenesis, some molecular markers might
be pathway specific. So, to reliably detect neoplasms, a
panel of molecular markers might be needed.
Biomarkers in Feces
Apart from these biological considerations with regard to
different stages of and pathways to cancer, we also need to
consider the way in which a biomarker gets into the
biological sample in which we want to measure it such as
feces, and whether it remains detectable. This is important
because most biomarkers are first “discovered” in neoplas-
tic tissues but will be sought in biological samples where
their chemical nature may be different.
Feces is comprised of water, undigested food, bacterial
biomass, shed cells, fragments of cells, and other products
from cells and vessels (blood and lymphatics). A clinically
usefultestforabiomarkermustbeabletodetectamoleculein
this complex and highly destructive mix that contains many
enzymes and other substances that will change the character-
istics of a marker, often by degradation.
The evidence indicates that neoplasms are associated
with “leakage” of cellular and vascular materials as well as
shedding of cells into feces. Colonocytes are continuously
shed into the fecal stream [19￿￿]. Markers can be classified
as those that leak through neoplasms, are secreted by
neoplasms, or arise by exfoliation [20]. To these we should
add shedding of cell fragments by events such as apoptosis
and release of tiny membranous vesicles (termed exosomes)
[21]. Biomarkers might arise from the neoplasm itself,
reflect a cellular response to the neoplasm, or simply result
from its physical presence (eg, leakage of plasma proteins).
Whatever the case, the biomarker needs to be stable to
ensure reliable detection. This might require a sample such
as feces to be collected under stringent conditions so as to
ensure its usefulness. This has proved to be crucial even for
DNA, which is known to be more stable than protein or
RNA in biological samples. A device appropriate for
ensuring that fecal DNA is of adequate quality has been
developed [22], but this is costly and logistically involved.
State
Proportion (%)
No neoplasia
Small Adenoma
Advanced
Adenoma
Cancer curable
Cancer incurable
D A
0% 20% 40% 60% 80% 100%
BC
Fig. 1 Conceptual presentation of the approximate proportion of a
typical Western population and the most advanced stage of colorectal
neoplasia reached by the time of death (life-time “state”). Points A–D
refer to examples of states at which a biomarker might provide
information (see text for discussion)
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simplicity of collection of a stable sample will be crucial
determinants of the practical usefulness of a biomarker.
Molecular Markers in Feces
As indicated above, it is known that biomarkers may gain
access to feces by many routes. It is also known that
neoplastic cells are less subject to apoptotic breakdown and
represent a proportionally higher fraction of fecal epithelial
cells when neoplasia is present [23]. Potential markers
could fall anywhere along the “omics” flow of information
processing relating to cell phenotype and behavior:
& Genomics: DNA, reflecting genetic (eg, mutations) and
epigenetic changes (eg, aberrant methylation) that are
characteristic of colorectal oncogenesis
& Transcriptomics: mRNA and microRNA, reflecting
expression patterns characteristic of neoplasia
& Proteomics: Proteins, reflecting abnormalities depen-
dent on translational or post-translational processing
& Metabolomics: Other biochemical events characteristic
of neoplasia.
Biochemical methods such as mutation analysis, next-
generation sequencing, microarrays, and proteomics may
all provide an option for detecting markers.
It is important to note that molecular markers in feces
potentially arise from any region of the aerodigestive
system. Ideally, one would use a marker that has selectivity
for colorectal neoplasia. A marker not specific for a given
organ-cancer raises the possibility of needing to pursue the
possibility of cancer anywhere in the aerodigestive tract.
This would be costly and of questionable benefit.
Fecal DNA Markers
DNA Markers in Feces: Pros and Cons
In a recent review, it has been pointed out that most studies
of stool-based DNA biomarkers have focused on the
detection of aberrant DNA originating from cancers
[19￿￿]. Several biological mechanisms help to increase the
potential to specifically detect tumor DNA in stool.
Whereas DNA in normal cells is degraded upon shedding
by rapid induction of apoptosis, shed tumor cells may
escape from apoptosis with reduced loss of DNA integrity
because apoptosis is reduced in neoplasms [23]. Thus, a
simple general measure of DNA integrity may be useful.
Genetic markers may, alternatively, be very specific. But,
many different point mutations characterize colorectal
oncogenesis and while a given gene might be a common
target for mutations, many different gene probes will be
needed to detect all the relevant mutations. Furthermore, the
mere presence of an oncogenic mutation in a cell does not
guarantee progression to cancer [1￿]. Consequently, muta-
tion detection is biologically limited, perhaps more so than
is detection of a bleeding phenotype using an FOBT.
Next to genetic alterations such as mutations, epigenetic
changes play an important role in deregulating gene expres-
sioninCRC[2]. Hypermethylation of the promoter region of
a gene, which can cause silencing of tumor suppressor genes
in many cancers, is a well studied example. Many genes
have been reported to be hypermethylated in colorectal
cancer [24], and these alterations appear to be early events in
carcinogenesis [19￿￿]. The latest developments in stool-based
DNA tests take advantage of both genetic (precise and
global) and epigenetic changes.
DNA Biomarker Evaluation
Bosch et al. [19￿￿] provide a comprehensive and thorough
review of stool-based DNA markers and the present review
will focus on the key issues arising from the many studies
undertaken. Bosch et al. found 19 papers looking at
multiple biomarkers in stool and 18 evaluating “single”
(or single class) gene markers [19￿￿]. For single markers,
mutations in K-ras and APC were initially studied and
eventually discarded as being useful in themselves. Most
studies were small, involved highly selected clinical (rather
than screen-detected) cohorts, and cases with adenomas
were generally not included; as a generalization, sensitiv-
ities for cancer ranged from around 40% to almost 90%.
Investigators progressed to include methylation and
other markers. A range of genes has been tested for
methylation—SFRP2, TFPI2, GATA4, NDRG4, OSMR,
and vimentin—with no one marker emerging as obviously
the best [19￿￿]. The DNA integrity assay for long-chain
DNA (the DIA assay) [23] has also been included [25￿]. As
a generalization, specificities ranged from 80% upwards for
these markers, making it clear that such molecular tests did
not guarantee specificity for neoplasia.
In parallel, investigators have pursued the value of
multiple markers, evaluated as a panel. Combinations of
mutation analysis of several genes with and without
markers of MSI (microsatellite instability), methylation,
and or DIA have been evaluated, again mainly in highly
selected clinical cohorts of patients with cancer. As a
generalization, detection was somewhat improved and
specificity tended to be in the range of 90% to 95% [19￿￿].
A large study promised much for DNA panels [26]. The
detection rate of cancer using a panel of markers based on
key tumor suppressor and oncogenes plus the DIA assay
and MSI, was 52% sensitive for cancer compared to 13%
using Hemoccult II GFOBT (P = 0.003). The sensitivity of
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advanced adenoma was poor, however: 18.2% for the DNA
panel compared to 10.8% for Hemoccult II (P = .001). The
performance of both tests in detecting advanced adenomas
was similarly disappointing (15.1% vs 10.7%, respective-
ly). In patients with negative colonoscopy, 5.6% tested
positive on fecal DNA (94.4% specific), compared to 4.8%
with Hemoccult II (95.2% specific). The study has been
criticized because of the uncharacteristically low sensitivity
for cancer of Hemoccult II.
Clearly, even a comprehensive DNA panel is biologically
limited. Furthermore, the specificity of fecal DNA was no
better than that of Hemoccult II. This might seem surprising,
but the adenoma-carcinoma sequence is propagated through
an accumulation of genomic events. Each event of itself isnot
capable of driving the oncogenic pathway to the point of
colonoscopically detectable neoplasia.
A similarly large study was subsequently reported using
some technological advances of the same panel [27￿￿]. This
time, the panel detected only 25% of cancers (less than did
the GFOBT Hemoccult) and 17% of adenomas greater than
1 cm, with a specificity of 96%.
Inclusion of vimentin methylation improved detection.
Ahlquist et al. [27￿￿] adapted the panel to comprise
vimentin together with mutation analysis of K-ras and
APC genes and detected 58% of cancers. Itzkowitz et al.
[28￿] combined vimentin with DIA to achieve 86%
sensitivity but specificity was inadequate: the two studies
returned specificities of 84% and 73%, respectively.
Table 1 summaries the larger DNA studies (more than
200 cases/controls) published since 2003.
Conclusions
DNA tests have great potential but as yet the ideal panel is
far from clear. The technology continues to evolve.
Thorough evaluation of such markers relative to different
molecular pathways of oncogenesis remains to be under-
taken. Costs of molecular tests remain high relative to
FOBT although with advances in technology this seems
likely to change. Unbiased mass population-based studies
have not yet been undertaken.
Fecal RNA Markers
RNA Markers in Feces: Pros and Cons
Tumor-derived RNA seems likely to get into stool by the
same processes as DNA. In addition, RNA might gain
access if cells secrete tiny membranous vesicles (termed
exosomes) that carry RNA species from the cell of origin
[21]. Various types of RNA, not just mRNA (which code
for proteins) but also microRNA (which are noncoding but
greatly influence gene expression), will gain access to feces
by these mechanisms. MicroRNAs have potential to be
biomarkers for cancers [31].
WeknowlessaboutthevalueofRNAmarkers.Acommon
approach has been to “discover” potential RNA-based
markers by examining gene expression profiles, called tran-
scriptomics, in neoplastic compared to normal tissue and then
pursuing those markers that appear to differentiate neoplasia
from non-neoplasia [8]. Underlying this is the concept that
gene expression patterns are unique for neoplasia (and
ideally for neoplasia within a given organ) and that the
differences between neoplasia and non-neoplasia are greater
than variations within non-neoplasia (eg, along the length of
the colon [32￿] or variations related to diet). Measuring
patterns of expression of large numbers of mRNA markers is
becoming commonplace in biological research, although
initial studies have focused on a single marker or small panel
when searching for fecal markers [19￿￿].
Unfortunately, RNA is less stable than DNA and assay
in feces creates major methodological challenges for
preservation of samples and RNA stability.
RNA Biomarker Evaluation
The potential for stool RNA markers to be informative has
been reviewed by Bosch et al. [19￿￿]. Studies have focused
principally on a single or small panel of markers.
To date the most studied mRNA marker in stool has
been PTGS2 (Cox-2, prostaglandin-synthase 2), but all
studies have been restricted to highly selected cases with
cancer. Table 2 shows that sensitivities have ranged from
50% to 90%, with specificities of 93% or higher [33–36].
Much larger cohorts that include disease controls are
required if we are to assess whether this biomarker realizes
its potential for use in a typical screening population.
Using larger panels of markers, for example, oligonucle-
otide microarrays, cancer-specific gene expression profiles
can bebuilt and used todiscriminatebetween cancer and non-
cancer.Usingthisapproach,one studyrevealedthatapanelof
nine oligonucleotide probes (PAP, REG1A, DPEP1, SEPP1,
RPL27A, ATP1B1, EEF1A1, SFN, and RPS11) gave a
sensitivity of 78% for CRC, with a specificity of 100%
[37]. However, they used fecal colonocytes as the specimen
for assay and applicability to stools is unclear.
Conclusions
Technological developments will have a big influence on
whether this approach based on RNA, whether mRNA or
microRNA, bears fruit. A panel of biomarkers seems likely
to be needed. For now, we are far from a feasible test for
clinical practice.
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Protein Markers in Feces: Pros and Cons
The detection of proteins in feces is relatively easy since
the protein of interest is often readily detected in small
sample volumes using inexpensive technologies. FIT are
just one example where simple qualitative or quantitative
methods for detection can be developed and provided at
a low cost. If new markers are shown to be stable in
stool, then simple test platforms such as membrane
lateral flow immunochemical devices or quantitative
latex-agglutination can be developed to provide simple
tests for mass screening.
Table 1 Summary of studies since 2003 that have tested DNA markers in stools and have included more than 200 cases/controls
Study Biomarker Method Study population Sensitivity Specificity
Single markers
Chen et al. [29], 2005 Vimentin Methylation analysis 94 cancers 46%
198 controls 90%
Calistri et al. [25￿], 2009 L-DNA FL-DNA, cutoff 25 ng 100 cancers 79%
100 controls 89%
Multiple markers
Tagore et al. [30], 2003 KRAS/ TP53 / APC Mutation analysis 52 cancers 64%
MSI MSI in BAT26 28 advanced adenomas 57%
DIA Presence of long DNA (four-site DIA) 212 controls 96%
Imperiale et al. [26], 2004 KRAS / TP53 / APC Mutation analysis 31 cancers 52%
MSI MSI in BAT26 403 advanced adenomas 15%
DIA Presence of long DNA (four-site DIA) 648 polyps 8%
1423 controls 95%
Ahlquist et al. [27￿￿], 2008 KRAS / TP53 / APC Mutation analysis 12 cancers 25%
MSI MSI in BAT26 135 adenomas >1 cm 17%
DIA Long DNA (four-site DIA) 469 adenomas <1 cm 4%
1473 controls 96%
Ahlquist et al. [27￿￿], 2008 KRAS / APC Mutation analysis 19 cancers 58%
Vimentin Methylation analysis 103 adenomas >1 cm 46%
75 controls 84%
Itzkowitz et al. [28￿], 2008 Vimentin Methylation analysis 42 cancers 86%
DIA Long DNA (two-site DIA) 241 controls 73%
Data extracted from Bosch et al. [19￿￿]
Table 2 Stool biomarker studies incorporating the RNA marker for cyclooxygenase-2 (PTGS2 [COX-2])
Study Biomarker Method Study population Sensitivity Specificity
Single markers
Kanaoka et al. [33], 2004 PTGS2 (COX-2) Nested RT-PCR 29 cancers 90%
22 controls 100%
Leung et al. [34], 2007 PTGS2 (COX-2) RT-PCR 20 cancers 50%
30 adenomas 4% 93%
30 controls
Multiple markers
Koga et al. [35], 2008 MMP7 / MYBL2 / PTGS2 (COX-2) / TP53 Quantitative RTPCR 166 cancers 58%
134 controls 88%
Takai et al. [36], 2009 PTGS2 (COX-2)/MMP7 Nested RT-PCR 62 cancers 90%
29 controls 100%
Data extracted from Bosch et al. [19￿￿]
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undergo degradation by proteolytic enzymes. Glycoproteins
are particularly subject to attack by glycosidases. Mass
spectrometry may well provide means for detecting
degraded markers and so “proteomics” might well deliver
useful biomarkers.
Protein Biomarker Evaluation
To date a moderately large number of markers have been
studied. Fifteen studies have been reviewed in depth [19￿￿].
Apart from immunochemical assays for human hemoglobin
itself, none has established a novel marker yet, although
most studies have been simple cohort studies with few
disease controls.
Markers range from proteins derived from blood or
plasma (eg, hemoglobin, calprotectin, haptoglobin) to
possibly tumor-derived markers such as M2-PK–pyruvate
kinase type M2, S100A12–S100 calcium-binding protein
A12, and TIMP-1–TIMP metallopeptidase inhibitor 1
[19￿￿].
Table 3 summarizes those papers that have included two
markers of interest, M2-PK and S100A12, that seem
derived from tumors. Tumor M2-PK appears to have
considerable potential [39, 40], with sensitivity for cancer
in a selected cohort of 78% to 85% and for adenomas in
general of 23% to 38%. Combining S100A12 with
hemoglobin, haptoglobin, and TIMP-1 in a study of over
500 patients shows sensitivity for cancer around 85% with
better than 95% specificity [41].
Markers arising from leakage of blood have shown some
ability to discriminate neoplasia from non-neoplasia but
these have not replaced FIT in practice. These include the
proteins haptoglobin [42, 43] and calprotectin, although the
latter is highly sensitive for inflammatory bowel disease
[44].
Conclusions
Some of these show promise, but as with other biomarkers,
until they are compared to a proven screening test such as
GFOBT and evaluated in large typical screening popula-
tions, the potential usefulness remains uncertain. Extensive
evaluation in disease controls is also needed because
markers evaluated so far are not necessarily tumor-specific
markers.
General Conclusions
The search for molecular biomarkers useful for screening
for colorectal cancer has not yet led to a simple test that can
replace FOBT. While good sensitivity has been achieved
for cancer, sensitivity for adenomas has not been adequate-
ly explored. Furthermore, molecular tests are not proving to
be any more specific for neoplasia than are FOBT,
Table 3 Studies of stool biomarkers testing for two proteins of interest, M2-PK (pyruvate kinase type M2) and S100A12 (S100 calcium-binding
protein A12)
Study Biomarker Method Study population Sensitivity Specificity
Single markers
Mulder et al. [38￿], 2007 Tumor M2-PK Immunoassay, cutoff 4 U/mL 52 cancers 85%
47 adenomas 28%
19 IBD 79%
63 controls 90%
Shastri et al. [39], 2008 Tumor M2-PK Immunoassay, cutoff 4 U/mL 55 cancers 78%
69 adenomas 38%
516 controls 74%
Haug et al. [40], 2008 Tumor M2-PK Immunoassay, cutoff 4 U/mL 106 advanced
adenomas
22%
216 adenomas 23%
649 controls 82%
Multiple markers
Karl et al. [41], 2008 S100A12 / hemoglobin-haptoglobin /
TIMP-1
Immunoassay, cutoff not
reported
186 cancers 82%–88%
113 advanced
adenomas
12%–20%
252 controls 95%–98%
Data extracted from Bosch et al. [19￿￿]
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DNA tests have been improved by combining mutation
detection with assessment of DNA integrity plus epigenetic
markers of neoplasia. RNA-based approaches are just
beginning to explore the full power of transcriptomics. So
far, no protein-based fecal test has proved better than fecal
immunochemical tests for hemoglobin. It seems likely that
a panel of markers will be required to ensure that the
various molecular pathways of oncogenesis and the
different patterns of gene expression are adequately
covered.
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